Mechanism of Action
OX2R Selectivity
Orexin-B binds OX2R with approximately 10-fold higher affinity than OX1R. OX2R activation on histaminergic neurons of the tuberomammillary nucleus drives histamine release, which promotes cortical arousal through H1 receptor activation. This histamine-dependent pathway is targeted by antihistamines that cause sedation as a side effect. OX2R is also expressed on dopaminergic neurons, pontine cholinergic neurons, and spinal cord neurons modulating motor tone.
Role in REM and Cataplexy Suppression
Pharmacological and genetic evidence suggests OX2R is more critical for REM suppression during wakefulness and non-REM sleep maintenance, while OX1R may have a larger role in emotional triggering of cataplexy. OX2R-selective agonists in narcolepsy models restore wakefulness and reduce cataplexy frequency. This receptor selectivity guides the development of OX2R agonists as more targeted narcolepsy therapies.
Research Summary
Narcolepsy OX2R Agonist Development
Phase 2TAK-925 (IV OX2R agonist) demonstrated proof-of-concept for OX2R-selective narcolepsy treatment in Phase 1 trials. Oral OX2R agonist programs (Takeda, Jazz Pharmaceuticals) are in active Phase 2 development. Selective OX2R agonism may offer narcolepsy symptom relief with potentially fewer side effects than dual OX1R/OX2R activation.
Sleep Architecture
Active ResearchOrexin-B infusion in animal models lengthens wake bouts and suppresses NREM/REM transitions. OX2R antagonists (SB-649868, others) reduce wake and increase NREM sleep. The OX2R pathway is the primary target of approved DORAs (suvorexant, lemborexant) for insomnia; OX1R blockade adds addiction-modulating properties to DORA pharmacology.
Calculate your Orexin-B dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Sleep-wake research | 1-10 nmol ICV or 5-30 nmol/kg IV in rodent models | Per session | ICV or intravenous |
Orexin-B is less used than orexin-A in research due to lower OX1R affinity; most translational work focuses on OX2R-selective agonists or orexin-A as the more potent dual agonist.
Interactions
Safety Profile
Similar to orexin-A; no distinct safety concerns for orexin-B vs orexin-A. OX2R agonist development programs (TAK-925 etc.) show expected wake-promoting effects without significant cardiovascular, hepatic, or renal adverse events in Phase 1. The targeted CNS expression of OX receptors limits peripheral organ effects.
References
- [1]Sakurai T, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides. Cell. 1998;92(4):573-585.
- [2]Mieda M, et al. Differential roles of orexin receptor-1 and -2 in the regulation of non-REM and REM sleep. J Neurosci. 2011;31(17):6518-6526.